206 related articles for article (PubMed ID: 34952899)
1. Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice.
Bi Z; Hong W; Que H; He C; Ren W; Yang J; Lu T; Chen L; Lu S; Peng X; Wei X
Signal Transduct Target Ther; 2021 Dec; 6(1):439. PubMed ID: 34952899
[TBL] [Abstract][Full Text] [Related]
2. Lung Expression of Human Angiotensin-Converting Enzyme 2 Sensitizes the Mouse to SARS-CoV-2 Infection.
Han K; Blair RV; Iwanaga N; Liu F; Russell-Lodrigue KE; Qin Z; Midkiff CC; Golden NA; Doyle-Meyers LA; Kabir ME; Chandler KE; Cutrera KL; Ren M; Monjure CJ; Lehmicke G; Fischer T; Beddingfield B; Wanek AG; Birnbaum A; Maness NJ; Roy CJ; Datta PK; Rappaport J; Kolls JK; Qin X
Am J Respir Cell Mol Biol; 2021 Jan; 64(1):79-88. PubMed ID: 32991819
[TBL] [Abstract][Full Text] [Related]
3. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice.
Zeng J; Xie X; Feng XL; Xu L; Han JB; Yu D; Zou QC; Liu Q; Li X; Ma G; Li MH; Yao YG
EBioMedicine; 2022 Jan; 75():103803. PubMed ID: 34979342
[TBL] [Abstract][Full Text] [Related]
4. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
[TBL] [Abstract][Full Text] [Related]
5. K18-hACE2 mice develop respiratory disease resembling severe COVID-19.
Yinda CK; Port JR; Bushmaker T; Offei Owusu I; Purushotham JN; Avanzato VA; Fischer RJ; Schulz JE; Holbrook MG; Hebner MJ; Rosenke R; Thomas T; Marzi A; Best SM; de Wit E; Shaia C; van Doremalen N; Munster VJ
PLoS Pathog; 2021 Jan; 17(1):e1009195. PubMed ID: 33465158
[TBL] [Abstract][Full Text] [Related]
6. Microglia Do Not Restrict SARS-CoV-2 Replication following Infection of the Central Nervous System of K18-Human ACE2 Transgenic Mice.
Olivarria GM; Cheng Y; Furman S; Pachow C; Hohsfield LA; Smith-Geater C; Miramontes R; Wu J; Burns MS; Tsourmas KI; Stocksdale J; Manlapaz C; Yong WH; Teijaro J; Edwards R; Green KN; Thompson LM; Lane TE
J Virol; 2022 Feb; 96(4):e0196921. PubMed ID: 34935438
[TBL] [Abstract][Full Text] [Related]
7. Modeling SARS-CoV-2 Infection in Mice Using Lentiviral hACE2 Vectors Infers Two Modes of Immune Responses to SARS-CoV-2 Infection.
Katzman C; Israely T; Melamed S; Politi B; Sittner A; Yahalom-Ronen Y; Weiss S; Abu Rass R; Zamostiano R; Bacharach E; Ehrlich M; Paran N; Nissim L
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062215
[TBL] [Abstract][Full Text] [Related]
8. Two new and effective food-extracted immunomodulatory agents exhibit anti-inflammatory response activity in the hACE2 acute lung injury murine model of COVID-19.
Liu S; Wang B; Chen T; Wang H; Liu J; Zhao X; Zhang Y
Front Immunol; 2024; 15():1374541. PubMed ID: 38807598
[TBL] [Abstract][Full Text] [Related]
9. Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis.
Albini A; Calabrone L; Carlini V; Benedetto N; Lombardo M; Bruno A; Noonan DM
Front Immunol; 2021; 12():718136. PubMed ID: 34646263
[TBL] [Abstract][Full Text] [Related]
10. Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion.
Fumagalli V; Ravà M; Marotta D; Di Lucia P; Laura C; Sala E; Grillo M; Bono E; Giustini L; Perucchini C; Mainetti M; Sessa A; Garcia-Manteiga JM; Donnici L; Manganaro L; Delbue S; Broccoli V; De Francesco R; D'Adamo P; Kuka M; Guidotti LG; Iannacone M
Sci Immunol; 2022 Jan; 7(67):eabl9929. PubMed ID: 34812647
[TBL] [Abstract][Full Text] [Related]
11. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.
Bao L; Deng W; Huang B; Gao H; Liu J; Ren L; Wei Q; Yu P; Xu Y; Qi F; Qu Y; Li F; Lv Q; Wang W; Xue J; Gong S; Liu M; Wang G; Wang S; Song Z; Zhao L; Liu P; Zhao L; Ye F; Wang H; Zhou W; Zhu N; Zhen W; Yu H; Zhang X; Guo L; Chen L; Wang C; Wang Y; Wang X; Xiao Y; Sun Q; Liu H; Zhu F; Ma C; Yan L; Yang M; Han J; Xu W; Tan W; Peng X; Jin Q; Wu G; Qin C
Nature; 2020 Jul; 583(7818):830-833. PubMed ID: 32380511
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target.
Xia B; Shen X; He Y; Pan X; Liu FL; Wang Y; Yang F; Fang S; Wu Y; Duan Z; Zuo X; Xie Z; Jiang X; Xu L; Chi H; Li S; Meng Q; Zhou H; Zhou Y; Cheng X; Xin X; Jin L; Zhang HL; Yu DD; Li MH; Feng XL; Chen J; Jiang H; Xiao G; Zheng YT; Zhang LK; Shen J; Li J; Gao Z
Cell Res; 2021 Aug; 31(8):847-860. PubMed ID: 34112954
[TBL] [Abstract][Full Text] [Related]
13. K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research.
Dedoni S; Avdoshina V; Camoglio C; Siddi C; Fratta W; Scherma M; Fadda P
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807384
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients.
Chen H; Liu W; Wang Y; Liu D; Zhao L; Yu J
EBioMedicine; 2021 Aug; 70():103500. PubMed ID: 34311326
[TBL] [Abstract][Full Text] [Related]
15. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
Mou H; Quinlan BD; Peng H; Liu G; Guo Y; Peng S; Zhang L; Davis-Gardner ME; Gardner MR; Crynen G; DeVaux LB; Voo ZX; Bailey CC; Alpert MD; Rader C; Gack MU; Choe H; Farzan M
PLoS Pathog; 2021 Apr; 17(4):e1009501. PubMed ID: 33836016
[TBL] [Abstract][Full Text] [Related]
16. Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory.
Carcaterra M; Caruso C
Med Hypotheses; 2021 Jan; 146():110412. PubMed ID: 33308936
[TBL] [Abstract][Full Text] [Related]
17. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review.
Qu L; Chen C; Yin T; Fang Q; Hong Z; Zhou R; Tang H; Dong H
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768911
[TBL] [Abstract][Full Text] [Related]
18. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
[TBL] [Abstract][Full Text] [Related]
19. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
20. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
